IMstam healthcare

IMstam Healthcare is a biotechnology company dedicated to developing transformative regenerative medicines using its proprietary Induced Myogenic Stem Cell (iMSC) platform. Founded on pioneering research from Duke University, the company focuses on treating severe muscle-related disorders such as Duchenne Muscular Dystrophy (DMD) and Volumetric Muscle Loss (VML). Their technology enables the efficient conversion of various cell types into myogenic progenitors, offering a scalable and potentially universal solution for muscle tissue repair and regeneration. IMstam aims to address significant unmet medical needs in the fields of orthopedics, aging, and genetic muscle diseases by restoring functional muscle mass.